Literature DB >> 25087170

Desferrioxamine as an appropriate chelator for 90Nb: comparison of its complexation properties for M-Df-Octreotide (M = Nb, Fe, Ga, Zr).

Valery Radchenko1, Stefan Busse2, Frank Roesch2.   

Abstract

The niobium-90 radioisotope ((90)Nb) holds considerable promise for use in immuno-PET, due to its decay parameters (t½ = 14.6h, positron yield=53%, Eß(+)(mean) = 0.35 MeV and Eß(+)(max) = 1.5 MeV). In particular, (90)Nb appears well suited to detect in vivo the pharmacokinetics of large targeting vectors (50-150 kDa). In order to be useful for immuno-PET chelators are required to both stabilize the radionuclide in terms of coordination chemistry and to facilitate the covalent attachment to the targeting vector. Different chelators were evaluated for this purpose in terms of radiolabelling efficiency and stability of the radiolabelled Nb(V) complex and in order to determine the most suitable candidate for conjugation to a biologically relevant targeting vector. For the purpose of studying the complexation properties the niobium radioisotope (95)Nb was used as an analogue of (90)Nb, by virtue of its longer half-life (35 days) and lower cost (reactor-based production). Acyclic and cyclic chelators were investigated, with desferroxamine [Df: (N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl) (hydroxy)amino]-4-oxobutanoyl} amino)pentyl]-N-hydroxysuccinamide)] emerging as the best candidate. Greater than 99% radiolabelling was achieved at room temperature over a wide pH range. The (95)Nb-Df complex is sufficiently stable for immuno-PET (<7% degradation over 7 days in vitro). As a proof-of-principle, a Df conjugate featuring a well-established targeting vector, (D)-Phe(1)-octreotide, was evaluated. The fast labelling kinetics of the unconjugated chelator (Df) were retained for Df-succinyl-(D)Phe(1)-octreotide (Df-OC), with>90% labelling after 1h at room temperature over the pH range 5-7. Stability studies, performed in vitro in serum at physiological temperature (37 °C), revealed that 87 ± 2% of the radiolabelled molecule remained intact after 7 days. Competition studies with relevant metal ions (zirconium((IV)), gallium((III)) and iron((III))) have been performed with Df-OC to gain insight to the relative stability [Nb-Df]-OC complex to transmetallation. At equimolar metal ion concentrations the [Nb-Df]-OC complex showed the greatest overall stability. The favourable radiolabelling characteristics of Df-OC and its stability indicate that Df is a potentially very useful chelator for the development of radiopharmaceuticals for (90)Nb-PET. Published by Elsevier Inc.

Entities:  

Keywords:  Chelators; Desferrioxamine; Df-Octereotide; Positron emitter (90)Nb; Stability

Mesh:

Substances:

Year:  2014        PMID: 25087170     DOI: 10.1016/j.nucmedbio.2014.06.006

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  5 in total

Review 1.  Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Authors:  K J H George; S Borjian; M C Cross; J W Hicks; P Schaffer; M S Kovacs
Journal:  RSC Adv       Date:  2021-09-21       Impact factor: 4.036

Review 2.  PET radiometals for antibody labeling.

Authors:  Eduardo Aluicio-Sarduy; Paul A Ellison; Todd E Barnhart; Weibo Cai; Robert Jerry Nickles; Jonathan W Engle
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

3.  In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores.

Authors:  Milos Petrik; Chuangyan Zhai; Zbynek Novy; Lubor Urbanek; Hubertus Haas; Clemens Decristoforo
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

4.  Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development.

Authors:  Darpan N Pandya; Nikunj Bhatt; Hong Yuan; Cynthia S Day; Brandie M Ehrmann; Marcus Wright; Ulrich Bierbach; Thaddeus J Wadas
Journal:  Chem Sci       Date:  2016-12-13       Impact factor: 9.825

5.  Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET.

Authors:  Marion Chomet; Maxime Schreurs; Maria J Bolijn; Mariska Verlaan; Wissam Beaino; Kari Brown; Alex J Poot; Albert D Windhorst; Herman Gill; Jan Marik; Simon Williams; Joseph Cowell; Gilles Gasser; Thomas L Mindt; Guus A M S van Dongen; Danielle J Vugts
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-05       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.